PMID- 21499011
OWN - NLM
STAT- MEDLINE
DCOM- 20111014
LR  - 20211020
IS  - 2092-6413 (Electronic)
IS  - 1226-3613 (Print)
IS  - 1226-3613 (Linking)
VI  - 43
IP  - 6
DP  - 2011 Jun 30
TI  - Antifibrotic effects of magnesium lithospermate B on hepatic stellate cells and 
      thioacetamide-induced cirrhotic rats.
PG  - 341-9
AB  - Magnesium lithospermate B (MLB) is one of the major active components of Salvia 
      miltiorrhizae. The anti-oxidative effects of Salvia miltiorrhizae have been 
      previously reported. The aim of this study was to investigate the effect of 
      purified MLB on hepatic fibrosis in rats and on the fibrogenic responses in 
      hepatic stellate cells (HSCs). Hepatic fibrosis was induced in rats by 
      intraperitoneal thioacetamide (TAA) injections over a period of 8 or 12 weeks. 
      MLB was orally administered daily by gavage tube. Serum AST and ALT levels in 
      TAA+ MLB group were significantly lower than those in TAA only group at week 8. 
      Hepatic fibrosis was significantly attenuated in TAA+MLB group than in TAA only 
      group at week 8 or 12. Activation of HSCs was also decreased in TAA+MLB group as 
      compared to TAA only group. Hepatic mRNA expression of alpha-smooth muscle actin 
      (alpha-SMA), TGF-beta1, and collagen alpha1(I) was significantly decreased in TAA+MLB group 
      as compared to TAA only group. Incubation with HSCs and MLB (>or=100 muM) for up 
      to 48 h showed no cytotoxicity. MLB suppressed PDGF-induced HSC proliferation. 
      MLB inhibited NF-KappaB transcriptional activation and monocyte chemotactic protein 1 
      (MCP-1) production in HSCs. MLB strongly suppressed H(2)O(2)-induced reactive 
      oxygen species (ROS) generation in HSCs, and MLB inhibited type I collagen 
      secretion in HSCs. We concluded that MLB has potent antifibrotic effect in 
      TAA-treated cirrhotic rats, and inhibits fibrogenic responses in HSCs. These data 
      suggest that MLB has potential as a novel therapy for hepatic fibrosis.
FAU - Paik, Yong Han
AU  - Paik YH
AD  - Department of Internal Medicine Yonsei University College of MedicineSeoul 
      120-752, Korea.
FAU - Yoon, Young Joon
AU  - Yoon YJ
FAU - Lee, Hyun Chul
AU  - Lee HC
FAU - Jung, Man Kil
AU  - Jung MK
FAU - Kang, So Hee
AU  - Kang SH
FAU - Chung, Sook In
AU  - Chung SI
FAU - Kim, Ja Kyung
AU  - Kim JK
FAU - Cho, Jae Yong
AU  - Cho JY
FAU - Lee, Kwan Sik
AU  - Lee KS
FAU - Han, Kwang Hyub
AU  - Han KH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Exp Mol Med
JT  - Experimental & molecular medicine
JID - 9607880
RN  - 0 (Actins)
RN  - 0 (Antioxidants)
RN  - 0 (Collagen Type I)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (NF-kappa B)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (smooth muscle actin, rat)
RN  - 075T165X8M (Thioacetamide)
RN  - 122021-74-3 (lithospermate B)
SB  - IM
MH  - Actins/genetics/metabolism
MH  - Animals
MH  - Antioxidants/*administration & dosage
MH  - Cell Proliferation/drug effects
MH  - Collagen Type I/genetics/metabolism
MH  - Drugs, Chinese Herbal/*administration & dosage
MH  - Fibrosis/prevention & control
MH  - Hepatic Stellate Cells/*drug effects/metabolism/pathology
MH  - Liver/*drug effects/metabolism/pathology
MH  - Liver Cirrhosis, Experimental/chemically induced/*drug therapy/physiopathology
MH  - Male
MH  - NF-kappa B/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reactive Oxygen Species/metabolism
MH  - Salvia miltiorrhiza/immunology
MH  - Thioacetamide/administration & dosage
MH  - Transcriptional Activation/drug effects
PMC - PMC3128912
EDAT- 2011/04/19 06:00
MHDA- 2011/10/15 06:00
PMCR- 2011/06/30
CRDT- 2011/04/19 06:00
PHST- 2011/04/19 06:00 [entrez]
PHST- 2011/04/19 06:00 [pubmed]
PHST- 2011/10/15 06:00 [medline]
PHST- 2011/06/30 00:00 [pmc-release]
AID - emm.2010.43.037 [pii]
AID - 10.3858/emm.2011.43.6.037 [doi]
PST - ppublish
SO  - Exp Mol Med. 2011 Jun 30;43(6):341-9. doi: 10.3858/emm.2011.43.6.037.